Narrow search
Showing 1 - 10 of 8,833
Cover Image
Exploring the relationship between EQ-5D, DLQI and PASI, and mapping EQ-5D utilities : a cross-sectional study in psoriasis from Hungary
Herédi, Emese; Rencz, Fanni; Balogh, Orsolya; … - In: The European journal of health economics : HEPAC ; … 15 (2014), pp. 111-119
Persistent link: https://www.econbiz.de/10010378378
Cover Image
Exploring the relationship between EQ-5D, DLQI and PASI, and mapping EQ-5D utilities: a cross-sectional study in psoriasis from Hungary
Herédi, Emese; Rencz, Fanni; Balogh, Orsolya; … - In: The European Journal of Health Economics 15 (2014) 1, pp. 111-119
compared to those with non-visible lesions, measured not only with DLQI but also with EQ-5D. In addition to demographic and … clinical variables, our model included health service utilisation variables related to psoriasis, and explained higher …
Persistent link: https://www.econbiz.de/10010993829
Cover Image
Comparative Effectiveness Without Head-to-Head Trials: A Method for Matching-Adjusted Indirect Comparisons Applied to Psoriasis Treatment with Adalimumab or Etanercept
Signorovitch, James E.; Wu, Eric Q.; Yu, Andrew P.; … - In: PharmacoEconomics 28 (2010) 10, pp. 935-945
a comparison of adalimumab and etanercept for the treatment of psoriasis. IPD from trials of adalimumab versus placebo … trials. Symptom improvements of ≥75% and ≥90% (as measured by the Psoriasis Area and Severity Index [PASI] score at … psoriasis. …
Persistent link: https://www.econbiz.de/10008519891
Cover Image
The Cost Effectiveness of Tapered versus Abrupt Discontinuation of Oral Cyclosporin Microemulsion for the Treatment of Psoriasis
Hakkaart-van Roijen, Leona; Verboom, Paul; Redekop, W. Ken - In: PharmacoEconomics 19 (2001) 5, pp. 599-608
cyclosporin in patients with chronic plaque psoriasis. Methods: A cost-effectiveness analysis was performed in parallel with a … plaque psoriasis inadequately controlled with topical treatment. Study perspective: The study was conducted from a societal … cyclosporin in patients with chronic plaque psoriasis. …
Persistent link: https://www.econbiz.de/10005590279
Cover Image
The Burden of Moderate to Severe Psoriasis: An Overview
Raho, Giovanna; Koleva, Daniela Mihajlova; Garattini, Livio - In: PharmacoEconomics 30 (2012) 11, pp. 1005-1013
Psoriasis is a chronic, immune-mediated skin disorder that affects 1-3% of the general population worldwide. While … considered a non-life-threatening disease, psoriasis represents a social and financial burden for patients and the healthcare …, patients with a diagnosis of psoriasis usually need lifelong care, which also means a lifetime of expenses. We aimed to conduct …
Persistent link: https://www.econbiz.de/10010579446
Cover Image
Outcome Measures of Efficacy Associated with a Web-Enabled Asthma Self-Management Programme: Findings from a Quasi-Experiment
Atherton, Martin - In: Disease Management and Health Outcomes 8 (2000) 4, pp. 233-242
Objective: To assess the efficacy of a World Wide Web-enabled asthma self-management intervention on quality-of-life indicators among self-selected participants with asthma. Design: A quasi-experimental design was used in which quality-of-life outcome indicators were derived from the Mini Asthma...
Persistent link: https://www.econbiz.de/10005242998
Cover Image
Improved Diabetes Control Through a Provider-Based Disease Management Program
Maljanian, Rose; Grey, Neil; Staff, Ilene; … - In: Disease Management and Health Outcomes 10 (2002) 1, pp. 1-8
Objective: The primary aim of this study was to evaluate the effectiveness of a newly implemented hospital-based diabetes mellitus disease management program. A secondary aim was to determine if relationships existed among variables. Design and setting: Effectiveness was evaluated in terms of...
Persistent link: https://www.econbiz.de/10005243030
Cover Image
Peginterferon alpha-2a (40kD) [Pegasys(R)] Improves HR-QOL Outcomes Compared with Unmodified Interferon alpha-2a [Roferon(R)-A]: In Patients with Chronic Hepatitis C
Rasenack, Jens; Zeuzem, Stefan; Feinman, S. Victor; … - In: PharmacoEconomics 21 (2003) 5, pp. 341-349
interferon alpha-2a. In addition to safety and efficacy, the impact on health-related quality of life may be an important …
Persistent link: https://www.econbiz.de/10005243108
Cover Image
Burden of Illness in Irritable Bowel Syndrome Comparing Rome I and Rome II Criteria
Badia, Xavier; Mearin, Fermin; Balboa, Agustin; Baro, Eva; … - In: PharmacoEconomics 20 (2002) 11, pp. 749-758
Objectives: To evaluate the burden of illness in irritable bowel syndrome (IBS), in terms of resource utilisation (direct and indirect) and health-related quality of life (HR-QOL), in individuals with IBS who meet Rome I and Rome II criteria. Methods: A cross-sectional study, carried out by...
Persistent link: https://www.econbiz.de/10005243189
Cover Image
Quality-of-Life Assessment in Patients with Benign Prostatic Hyperplasia: Effects of Various Interventions
Batista-Miranda, Jose-Emilio; Diez, Marta De la Cruz; … - In: PharmacoEconomics 19 (2001) 11, pp. 1079-1090
A literature search was conducted to review quality-of-life (QOL) measurement in patients with benign prostatic hypertrophy (BPH). The different QOL instruments are discussed in relation to their correlation with symptom evaluation in studies of treatment options for BPH. Symptom evaluation of...
Persistent link: https://www.econbiz.de/10005243203